Metastatik tiroid kanserinde sistemik tedavi etkinliğinin retrospektif olarak değerlendirilmesi

Abstract

Amaç: Tiroid kanserleri, endokrin kanserleri içerisinde en

sık görülen kanserdir. Metastatik tiroid kanserlerinin sistemik

tedavisinde güncel yaklaşımlar faz II çalışması olan kemoterapi

ve faz III çalışması tirozin kinaz inhibitörleridir. Çalışmamızda,

metastatic tiroid kanserli hastalarda sistemik tedavilerin etkinliğini

belirlemeyi hedefledik.

Gereçler ve Yöntemler : Maslak Acıbadem Hastanesi Tıbbi

Onkoloji Kliniği’ne 2008 ile 2015 yılları arasında ve 2016 ile 2018

yılları arasında Sağlık Bakanlığı Sağlık Bilimleri Üniversitesi

Ümraniye Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji

Kliniği’ne gelen ,hem metastaz gelişmesi, hem de radyoaktif iyot

tedavisine refrakter olması nedeniyle sistemik tedavi amacıyla

yönlendirilmiş olan 57 metastatik tiroid kanseri olan hastaların

dosyaları retrospektif olarak analiz edildi.

Bulgular : Hastaların, %52’si (30 hasta) kadın, %48’i (27

hasta) erkek, yaş ortalaması 57,11, ve tamamı 18 yaşın üzerinde

idi. Hastaların, %59,8’i (35 hasta) iyi diferansiye tiroid kanseri,

%29,8’i (17 hasta) medüller tiroid kanseri, %5,3’ü (3 hasta)

anaplastik tiroid kanseri, % 3,5’i ( 2 hasta) az diferansiye kanseri

ve %1,8’i ( 1 hasta) medüller-papiller senkron kanseri idi. Birinci

seri sistemik tedavi yanıtı tüm 57 olguda değerlendirildiğinde

progresyonsuz sağ kalım (PFS) süresi kemoterapi ve sorafenib için

sırasıyla 4,25 ve 6,33 ay olarak tespit edildi (P:0.035). İkinci seride

toplam 57 hasta dosyası retrospektif olarak değerlendirildi ve PFS,

kemoterapi alan ve sorafenib kullanılan hastalarda 4,1 ve 7,77 ay

olarak bulundu (P<0.001).

Sonuç: Radyoaktif iyot tedavisine refrakter olarak diferansiye

tiroid kanserleri ve medüller tiroid kanserleri tedavisinde tirozin

kinaz inhibitörü kullanılmaktadır. Tiroid kanserlerinde lenvatinib,

sorafenib ve vandetanibin progresyonsuz sağkalım üzerine olan

etkisi sistemik kemoterapiden üstün bulunmuştur. Özellikle,

ülkemizde olmak üzere radyoaktif iyod tedavisine refrakter iyi

diferansiye tiroid kanserlerinde sorafenib, etkinlik ve toksisite

profili açısından tercih edilebilecek bir sistemik tedavi seçeneğidir.

Keywords

• Tiroid,Kanser,Sorafenib

A retrospective analysis of efficacy of systemic therapy in metastatic thyroid cancer

Abstract

Objective: Thyroid cancer is the most common type of endocrine

cancer. The current approaches in the systemic therapies of

metastatic thyroid cancers are chemotherapy that is investigated in

phase II clinical trials and tyrosine kinase inhibitors, investigated

in phase III clinical trials. The aim of this study was to evaluate the

efficacy of systemic therapies in metastatic thyroid cancer patients.

Materials and Methods: We investigated 57 patients

retrospectively, diagnosed with thyroid cancer who were referred to

Maslak Acibadem Hospital Medical Oncology Department between

2008-2015 and Umraniye Training and Research Hospital between

2016-2018. They had received systemic treatment due to the refractory

profile to radioiodine therapy and metastatic thyroid cancer.

Results: Medical records of 57 patients with metastatic thyroid

cancer, who were referred for systemic therapy were retrospectively

analysed. 52% (n:30) of the cases were women and 48% (n:27)

were men, and the mean age was 57.11 years. All patients was

above the age of 18. Of the patients, 59.8% (n:35) had well

differentiated thyroid cancer, 29.8% (n:17) had medullary thyroid

cancer, 5.3% (n:3) had anaplastic thyroid cancer, 3.5% (n:2) had

poorly differentiated thyroid cancer and 1.8% (n:1) had medullarypapillary

synchronous cancer. When first line systemic therapy

was evaluated for all 57 patients, progression free survival (PFS)

was found 4.25 and 6.33 months for chemotherapy and sorafenib,

respectively (P:0.035). All cases were evaluated retrospectively

for second line systemic therapy and PFS was 4.1 and 7.77 months

for chemotherapy and sorafenib, respectively (P<0.001).

Conclusion: Tyrosine kinase inhibitors are used in the treatment

of radioactive iodine-refractory differentiated thyroid cancers and

medullary thyroid cancers. The effect of lenvatinib, sorafenib and

vandetanib on progression-free survival in thyroid cancers is found

to be superior to systemic chemotherapy. It was concluded that

sorafenib is a systemic treatment option which can be preferred in

terms of efficacy and toxicity profile in radioactive iodine refractory

well-differentiated thyroid cancer especially in our country.

Keywords

• Thyroid,Cancer,Sorafenib

References

1. 1. Shah JP. Thyroid carcinoma: Epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol 2015; 13(4 Suppl 4): 3-6.
2. 2. Brown RL, De Souza JA, Cohen EE. Thyroid cancer: Burden of illness and management of disease. J Cancer 2011;2:193- 199. doi: https://doi.org/10.1530/ERC-16-0372.
3. 3. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 (suppl 1): vii110–9. doi.org/10.1093/annonc/mds230.
4. 4. Barut F. Tiroid kanserlerinin patolojisi. Turkiye Klinikleri J Med Oncol-Special Topics 2017;10:10-2.
5. 5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 ;19:1167-214. doi: 10.1089/ thy.2009.0110.
6. 6. Albero A, Lopéz JE, Torres A, et al. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endoc Relat Cancer 2016;23:R71-84. doi: 10.1530/ERC-15-0194.
7. 7. Kormaz T, Er Ö. Tiroid kanserlerinde tirozin kinaz inhibitör tedavisi, kemoterapi ve gelecekteki olası tedaviler. Turkiye Klinikleri J Med Oncol-Special Topics 2017;10:50-5.
8. 8. Baran A., Yılmaz M. Tiroid kanserlerinde kemoterapi ve hedefe yönelik tedaviler. Türkiye Kanserle Savaş Vakfı Kanser Gündemi Tiroid Kanseri 2015;3/3:62-4.

9. 9. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Eng Med J 1974;290:193-7. doi:10.1056 /NEJM 197.401.242900404
10. 10. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60. doi: 10.1002/1097- 0142(19851101)56:9<2155.
11. 11. Matuszczyk A, Petersenn S, Voigt W, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2010;42:61-4. doi: 10.1055/s-0029.123.8294.
12. 12. Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9. doi: 10.1200/JCO.2008.16.3279.
13. 13. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84. doi: 10.1200/JCO.2008.18.2717.
14. 14. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28. doi: 10.1016/S0140- 6736(14)60421-9.
15. 15. Schlumberger M, Tahara M, Wirth LJ et al. Lenvatinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372:621-30. doi: 10.1056/NEJMoa1406470